case_images: PMC5390560_01
case_images: Audiograms of the patient obtained before starting the second treatment phase.
case_images: CRIOT2017-5304242.001.jpg
case_images: PMC5390560_01_CRIOT2017-5304242.001.jpg
case_images: fig1
case_images: He presented bilateral, sensorineural, high frequency hearing loss with a pure-tone average of 49 dB HL in both ears (Figure 1).
case_images: PMC5390560_02
case_images: Device configuration. The tinnitus neuromodulation therapy device (neurostimulator T30 CR, left) applied the acoustic CR neuromodulation signals via cable to the "streamer" (Phonak ComPilot, middle) that in turn sent the therapy signals via radio frequency link to the two hearing aids (Phonak Audeo V50, right).
case_images: CRIOT2017-5304242.002.jpg
case_images: PMC5390560_02_CRIOT2017-5304242.002.jpg
case_images: fig2
case_images: Subsequently (2015-2016), he was treated for 12 weeks with the same neuromodulation therapy device (T30 CR, Neurotherapies Reset GmbH, Julich, Germany, a company of the Brook Henderson Group Limited) but connected to an external "streamer" (Phonak ComPilot,) that was a component of commercially available hearing aids (Phonak Audeo V50 Sonova AG, Stafa, Switzerland), Figure 2.
case_images: PMC5390560_03
case_images: THI, VASL, and VASA scores for acoustic CR neuromodulation therapy (black bar baseline, white bar after treatment) for two treatment phases. The first treatment phase (a) used only a CR neuromodulation device (T30 CR device with custom earphones only). The second treatment phase (b) used the same neuromodulation device (T30 CR) but combined with a streamer (Phonak ComPilot) wirelessly connected to hearing aids (Phonak Audeo V50).
case_images: CRIOT2017-5304242.003.jpg
case_images: PMC5390560_05_CRIOT2017-5304242.003.jpg
case_images: fig3
case_images: THI score was reduced by 70% to 12 points, the VASL score was reduced by 32% to 63 points, and the VASA score was reduced by 32% to 63 points, Figure 3(b).
case_images: PMC5390560_04
case_images: PMC5390560_05
case_images: THI, VASL, and VASA scores for acoustic CR neuromodulation therapy (black bar baseline, white bar after treatment) for two treatment phases. The first treatment phase (a) used only a CR neuromodulation device (T30 CR device with custom earphones only). The second treatment phase (b) used the same neuromodulation device (T30 CR) but combined with a streamer (Phonak ComPilot) wirelessly connected to hearing aids (Phonak Audeo V50).
case_images: CRIOT2017-5304242.003.jpg
case_images: PMC5390560_05_CRIOT2017-5304242.003.jpg
case_images: fig3
case_images: THI score was reduced by 70% to 12 points, the VASL score was reduced by 32% to 63 points, and the VASA score was reduced by 32% to 63 points, Figure 3(b).